Thc Therapeutics Stock Probability of Future Pink Sheet Price Finishing Over 50.23

THCT Stock  USD 0.0005  0  89.13%   
THC Therapeutics' future price is the expected price of THC Therapeutics instrument. It is based on its current growth rate as well as the projected cash flow expected by the investors. This tool provides a mechanism to make assumptions about the upside potential and downside risk of THC Therapeutics performance during a given time horizon utilizing its historical volatility. Check out THC Therapeutics Backtesting, THC Therapeutics Valuation, THC Therapeutics Correlation, THC Therapeutics Hype Analysis, THC Therapeutics Volatility, THC Therapeutics History as well as THC Therapeutics Performance.
  
Please specify THC Therapeutics' target price for which you would like THC Therapeutics odds to be computed.

THC Therapeutics Target Price Odds to finish over 50.23

The tendency of THC Pink Sheet price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
Current PriceHorizonTarget PriceOdds to move over $ 50.23  or more in 90 days
 0.0005 90 days 50.23 
close to zero percent
Based on a normal probability distribution, the odds of THC Therapeutics to move over $ 50.23  or more in 90 days from now is close to zero percent (This THC Therapeutics probability density function shows the probability of THC Pink Sheet to fall within a particular range of prices over 90 days) . Probability of THC Therapeutics price to stay between its current price of $ 0.0005  and $ 50.23  at the end of the 90-day period is close to 99 .
Given the investment horizon of 90 days THC Therapeutics has a beta of -19.97. This usually implies as returns on its benchmark rise, returns on holding THC Therapeutics are expected to decrease by similarly larger amounts. On the other hand, during market turmoils, THC Therapeutics is expected to outperform its benchmark. In addition to that THC Therapeutics has an alpha of 12.2288, implying that it can generate a 12.23 percent excess return over Dow Jones Industrial after adjusting for the inherited market risk (beta).
   THC Therapeutics Price Density   
       Price  

Predictive Modules for THC Therapeutics

There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as THC Therapeutics. Regardless of method or technology, however, to accurately forecast the pink sheet market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the pink sheet market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of THC Therapeutics' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Hype
Prediction
LowEstimatedHigh
0.000.000550.03
Details
Intrinsic
Valuation
LowRealHigh
0.000.000550.03
Details

THC Therapeutics Risk Indicators

For the most part, the last 10-20 years have been a very volatile time for the stock market. THC Therapeutics is not an exception. The market had few large corrections towards the THC Therapeutics' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold THC Therapeutics, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of THC Therapeutics within the framework of very fundamental risk indicators.
α
Alpha over Dow Jones
12.23
β
Beta against Dow Jones-19.97
σ
Overall volatility
0
Ir
Information ratio 0.1

THC Therapeutics Alerts and Suggestions

In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of THC Therapeutics for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for THC Therapeutics can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.
THC Therapeutics is way too risky over 90 days horizon
THC Therapeutics has some characteristics of a very speculative penny stock
THC Therapeutics appears to be risky and price may revert if volatility continues
THC Therapeutics has high likelihood to experience some financial distress in the next 2 years
THC Therapeutics currently holds 925.89 K in liabilities with Debt to Equity (D/E) ratio of 18.7, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. THC Therapeutics has a current ratio of 0.01, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist THC Therapeutics until it has trouble settling it off, either with new capital or with free cash flow. So, THC Therapeutics' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like THC Therapeutics sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for THC to invest in growth at high rates of return. When we think about THC Therapeutics' use of debt, we should always consider it together with cash and equity.
Net Loss for the year was (1.89 M) with profit before overhead, payroll, taxes, and interest of 0.
THC Therapeutics currently holds about 3.82 K in cash with (388.48 K) of positive cash flow from operations.
Roughly 31.0% of THC Therapeutics outstanding shares are owned by corporate insiders

THC Therapeutics Price Density Drivers

Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of THC Pink Sheet often depends not only on the future outlook of the current and potential THC Therapeutics' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. THC Therapeutics' indicators that are reflective of the short sentiment are summarized in the table below.
Common Stock Shares Outstanding16.6 M
Cash And Short Term Investments296.1 K

THC Therapeutics Technical Analysis

THC Therapeutics' future price can be derived by breaking down and analyzing its technical indicators over time. THC Pink Sheet technical analysis helps investors analyze different prices and returns patterns as well as diagnose historical swings to determine the real value of THC Therapeutics. In general, you should focus on analyzing THC Pink Sheet price patterns and their correlations with different microeconomic environments and drivers.

THC Therapeutics Predictive Forecast Models

THC Therapeutics' time-series forecasting models is one of many THC Therapeutics' pink sheet analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models are widely used for non-stationary data. Non-stationary data are called the data whose statistical properties, e.g., the mean and standard deviation, are not constant over time, but instead, these metrics vary over time. This non-stationary THC Therapeutics' historical data is usually called time series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the pink sheet market movement and maximize returns from investment trading.

Things to note about THC Therapeutics

Checking the ongoing alerts about THC Therapeutics for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for THC Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
THC Therapeutics is way too risky over 90 days horizon
THC Therapeutics has some characteristics of a very speculative penny stock
THC Therapeutics appears to be risky and price may revert if volatility continues
THC Therapeutics has high likelihood to experience some financial distress in the next 2 years
THC Therapeutics currently holds 925.89 K in liabilities with Debt to Equity (D/E) ratio of 18.7, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. THC Therapeutics has a current ratio of 0.01, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist THC Therapeutics until it has trouble settling it off, either with new capital or with free cash flow. So, THC Therapeutics' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like THC Therapeutics sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for THC to invest in growth at high rates of return. When we think about THC Therapeutics' use of debt, we should always consider it together with cash and equity.
Net Loss for the year was (1.89 M) with profit before overhead, payroll, taxes, and interest of 0.
THC Therapeutics currently holds about 3.82 K in cash with (388.48 K) of positive cash flow from operations.
Roughly 31.0% of THC Therapeutics outstanding shares are owned by corporate insiders

Additional Tools for THC Pink Sheet Analysis

When running THC Therapeutics' price analysis, check to measure THC Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy THC Therapeutics is operating at the current time. Most of THC Therapeutics' value examination focuses on studying past and present price action to predict the probability of THC Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move THC Therapeutics' price. Additionally, you may evaluate how the addition of THC Therapeutics to your portfolios can decrease your overall portfolio volatility.